ELEV – elevation oncology, inc. - common stock (US:NASDAQ)
Stock Stats
News
Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Citigroup Inc. to a "market perform" rating.
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 [Yahoo! Finance]
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $1.00 price target on the stock, down previously from $5.00.
Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Form 8-K Elevation Oncology, Inc. For: Apr 03
Form 8-K Elevation Oncology, Inc. For: Mar 31
Form SCHEDULE 13G Elevation Oncology, Inc. Filed by: BML Investment Partners, L.P.
Form 8-K Elevation Oncology, Inc. For: Mar 20
Form 8-K Elevation Oncology, Inc. For: Mar 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.